Crucell Holland B.v.

Janssen Vaccines & Prevention B.v.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Beth Israel Deaconess Medical Center, Inc.

Bavarian Nordic A/s

US Government as Represented by the Secretary of the Army

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Glaxosmithkline Biologicals Sa

Maria Grazia Pau

Lennart Holterman

Antonius J H Stegmann

Jorn Kaspers

Alphonsus G C M UytdeHaag

Dan H Barouch

Frank Tomaka

Johanna Schuitemaker

Benoit Christophe Stephan Callendret

Gary J Nabel

Ronald Vogels

Robin Steigerwald

Jaap Goudsmit

Govert Johan Schouten

Nancy J Sullivan

Ulrike Dirmeier

Ariane Volkmann

Danielle Van Manen

Lucy A Ward

Stefan Kostense

Mieke Caroline Sprangers

Jennifer Anne Hendriks

Zhi-yong Yang

Menzo Jans Emco Havenga

Bimal Chakrabarti

Jerome H Kim

Nelson L Michael

Dirk Jan Elbertus Opstelten

Alphonsus Gerardus Uytdehaag

Jintanat Ananworanich

Merlin Robb

Giuseppe Marzio

Alphonsus Gerardus Cornelis Maria Uytdehaag

Cheng Cheng

Menzo Havenga

Zhi-Yong Yang

Clement Asiedu

Roland Christian Zahn

Antonius Johannes Hendrikus Stegmann

V Ann Stewart

Dirk Jan Opstelten

Antonius Johannes Stegmann

Joseph D Glaxosmithkline Cohen

Patrice M Glaxosmithkline Dubois

Donald Heppner

The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.

Methods and compositions for inducing protective immunity against filovirus infection

Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV.

Compositions and methods for inducing protective immunity against human immunodeficiency virus infection

Compositions, vaccines and methods using adenovirus vectors for priming and boosting vaccinations for inducing protective immunity against a Marburg virus infection are described.

Methods and compositions for inducing protective immunity against a Marburg virus infection

Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.

Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

Compositions, vaccines and methods for inducing protective immunity against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of HIV.

Methods for inducing protective immunity against human immunodeficiency virus infection

Methods and compositions for inducing protective immunity against human immunodeficiency virus infection

Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.

Adenovirus serotype 26 and serotype 35 filovirus vaccines

The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.

Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures

The present invention discloses methods for producing and/or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle. The invention also provides a method for selective propagation of a set of virus particles, such as influenza virus particles present in an influenza isolate, which have an affinity for receptors comprising a specific glycosylation residue.

Production of viruses, viral isolates and vaccines

Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against differentinfections, such as infections byor. Codon-optimized circumsporozoite genes are disclosed. Replication-defective adenoviruses may be used, derived from serotypes that encounter low titers of neutralizing antibodies. Also described is the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.

Recombinant viral-based malaria vaccines

Described are new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, also described are new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Settings for recombinant adenoviral-based vaccines

Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector

Growing community of inventors

Leiden, Netherlands

Maria Grazia Pau